.
.
.
.

AstraZeneca side effects reviewed in India after European concerns

Published: Updated:

India will carry out a deeper review of post-vaccination side effects from the AstraZeneca shot next week although no cases of blood clots have been reported so far, an official told AFP Saturday.

New Delhi decided to conduct the review after several countries suspended rollout over blood clot fears even as the World Health Organization said there was no reason to stop using AstraZeneca's Covid-19 jab.

Read the latest updates in our dedicated coronavirus section.

Denmark, Norway and Iceland paused use of the drug maker’s shot as a precaution after isolated reports of recipients developing blood clots.

“We are looking at all the adverse events, particularly serious adverse events like deaths and hospitalization. We will come back if we find anything of concern,” N.K. Arora, a member of India's national task force on Covid-19, told AFP.

India has given at least 28 million shots in its vast vaccination program, most of them AstraZeneca's which are produced at the Serum Institute of India.

New Delhi has also gifted and allowed exports of millions of these jabs to around 70 countries over the last few weeks as a part of its vaccine diplomacy.

Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, Jan. 16, 2021. (File photo: Reuters)
Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, Jan. 16, 2021. (File photo: Reuters)

Arora said there was “no immediate issue of concern as number of adverse events (in India) is very, very low. We are relooking at (adverse events that were reported) to see if there was any issue of blood clotting.”

“As of yesterday there were 59 or 60 deaths, and they were all coincidental,” the doctor said, adding hospitalization cases were being re-examined.

“In fact there is a real effort from our side that once complete investigation is done, to put its results in public domain, on the ministry of health website,” Arora added.

India has been using AstraZeneca and indigenous vaccine giant Bharat Biotech's Covaxin in its rapidly expanding vaccination drive at home.

At least two million people were vaccinated on Friday alone, and this ramp up comes at a time when Covid-19 cases are rising across different Indian states after weeks of decline.

The western state of Maharashtra has announced fresh restrictions and a week-long lockdown in one of its big cities, Nagpur, after the recent spike across the region.

Fresh restrictions including curbs on movement and public gatherings were also reintroduced in some pockets of the state, which is also expected to impact the economic recovery in its industrial belt.

Read more:

India seeks investment for vaccine production to match China’s push-source

India records biggest one-day spike in COVID-19 cases

Indian vaccine giant Serum Inst. warns of supply hit from US raw materials export ban